Risk factors
Corbus Pharmaceuticals Holdings (CRBP) risk factors
Item 1A of every Corbus Pharmaceuticals Holdings, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
59 risks, 1 new, 6 reworded since the prior year. Clinical trial progress is highlighted with updates for drug candidates CRB-701, CRB-601, and CRB-913 across various phases. Personnel retention and stock option reliance are introduced as new operational risks. Financial disclosures updated to reflect $163.3 million in cash and investments for 2025.
Filed Mar 09, 2026 - FY2024 10-K risk factors
58 risks. Clinical trials for drug candidate CRB-701 rely heavily on external partners like CSPC in China. Operations depend entirely on clinical success with no commercial products or revenues yet. Substantial ongoing losses are funded by existing cash reserves of $149.1 million.
Filed Mar 11, 2025